Abstract

Radiation‐associated sarcoma (RAS) is a rare complication of radiation therapy (RT) to breast cancer (BC). This study explored RAS after RT to BC in a nationwide population‐based material. The Finnish Cancer Registry was queried for patients with BC treated during 1953‐2014 who were later diagnosed with a secondary sarcoma in 1953‐2014. Registry data, patient files, and sarcoma specimens were analyzed to confirm diagnosis and location of RAS at or close to the RT target volume. A total of 132 512 patients were diagnosed with invasive BC during the study period. A subsequent sarcoma was diagnosed in 355 patients. After exclusion, 96 RAS were identified. Angiosarcoma (AS) was the most prevalent histology in 50 (52%) of 96 patients. However, the first radiation‐associated AS was diagnosed in a patient treated for BC with breast‐conserving surgery in 1984, and thereafter, the proportion of AS continuously increased. The 5‐year sarcoma‐specific survival was 75.1% for RAS treated with a curative intent. The distribution of histologic subtypes of RAS has changed during the 60 years of this registry study. The first radiation‐associated AS was diagnosed in 1989, and presently, AS is the most common histologic subtype of RAS. It is possible that changes in BC treatment strategies are influencing the characteristics of RAS.

Highlights

  • Breast cancer (BC) comprised 23% of global cancer incidence and 14% of global cancer mortality among women in 2008 showing an increase in both incidence and mortality worldwide by the year 2012.1 Most BCs are diagnosed at an early stage for which the gold standard of treatment is breast-­ conserving surgery combined with radiation therapy (RT).[2]

  • 355 patients were diagnosed with a subsequent sarcoma during the study period vs 187.72 expected (SIR 1.89 [95% confidence intervals 1.7-2­ .09])

  • During the last three decades of study period, the incidence ratio of AS increased compared to the incidence ratio of other secondary sarcomas

Read more

Summary

Introduction

Breast cancer (BC) comprised 23% of global cancer incidence and 14% of global cancer mortality among women in 2008 showing an increase in both incidence and mortality worldwide by the year 2012.1 Most BCs are diagnosed at an early stage for which the gold standard of treatment is breast-­ conserving surgery combined with radiation therapy (RT).[2]The side effects of RT are typically transient skin reactions, but in rare cases, RT is associated with the development of sarcoma (radiation-­associated sarcoma [RAS]).

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.